Hjem › Kronisk lymfatisk leukæmi › Alabama
Kronisk lymfatisk leukæmi kliniske forsøg i Alabama
7 studier for Kronisk lymfatisk leukæmi søger deltagere på steder i Alabama.
Byer i Alabama
Officiel studietekst (engelsk)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- University of Alabama at Birmingham Cancer Center, Birmingham
RekruttererFase 3
Alder 65 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07321652A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- University of Alabama At Birmingham Hospital, Birmingham
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- University of Alabama At Birmingham Hospital, Birmingham
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- USA Mitchell Cancer Institute ( Site 0014), Mobile
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06136559A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Mitchell Cancer Institute, Mobile
RekruttererFase 4
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07218341Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT04588922HPC Offered for PRESERVE Expansion
- University of Alabama, Birmingham, Birmingham
RekruttererObservationsstudie
Alder 12 til 80 · Alle køn · Opdateret 28. aug. 2025 · NCT07145411Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.